Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma
Eribulin lengthened survival by two months compared with dacarbazine in previously treated liposarcoma and leiomyosarcoma, with the entire benefit in liposarcoma, where survival improved by seven months, leading to its approval for that subtype.
Overview
Phase 3 trial of 452 patients with advanced liposarcoma or leiomyosarcoma after at least two prior regimens randomised to eribulin or dacarbazine.
Median overall survival was 13.5 versus 11.5 months (hazard ratio 0.77) overall, and 15.6 versus 8.4 months in liposarcoma (hazard ratio 0.51) with no difference in leiomyosarcoma; progression-free survival was similar between arms.
- Median overall survival 13.5 vs 11.5 months overall; hazard ratio 0.77.
- Liposarcoma: 15.6 vs 8.4 months; hazard ratio 0.51.
Eribulin is an approved later-line treatment for liposarcoma, one of the few sarcoma drugs with a demonstrated survival benefit.
- No progression-free survival benefit, an unusual pattern.
- Dacarbazine is an active comparator in leiomyosarcoma.
Similar pages
not linked directly; found by shared links- Key paperTrabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure
Shares Dacarbazine, Liposarcoma.
- CancerRetroperitoneal sarcoma
Shares Dacarbazine, Liposarcoma, Eribulin.
- CancerSoft tissue sarcoma of the extremity (localised and advanced)
Shares Liposarcoma, Eribulin.